Encouraged by these results, ImmunoGenesis announced in late 2020 the initiation of a Phase 2 trial exploring evofosfamide in combination with both anti-CTLA-4 and anti-PD-1 therapies for patients with castration-resistant prostate cancer, pancreatic ductal adenocarcinoma, and HPV-negative HNSCC [195]. This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.